Evidence map›Paper›PMID 29570800›Full record

ArticleThe Journal of pathology2018

DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients.

Gerwin Heller, Corinna Altenberger, Irene Steiner, Thais Topakian, Barbara Ziegler, Erwin Tomasich, György Lang, Adelheid End-Pfützenreuter, Sonja Zehetmayer, Balazs Döme and 4 more

Open access · hybridAbstract read
In one paragraph

Article in The Journal of pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. A Robust NSCLC Biomarker- miR-7-5p: ItsMicroRNA (Shariqah, United Arab Emirates) · 2025
    Article
  5. Review
  6. Article
  7. miR-137: a potential therapeutic target for lung cancer.Frontiers in cell and developmental biology · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. MiR-3150b inhibits hepatocellular carcinoma cell proliferation, migration and invasion by targeting GOLPH3.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020
    Article
  14. Article
  15. MiR-3150b-3p inhibits the progression of colorectal cancer cells via targeting GOLPH3.Journal of investigative medicine : the official publication of the American Federation for Clinical Research · 2020
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Gerwin HellerDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Corinna AltenbergerDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Irene SteinerCentre for Medical Statistics, Informatics and Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, Vienna, Austria.
Thais TopakianDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Barbara ZieglerDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Erwin TomasichDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
György LangComprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Adelheid End-PfützenreuterComprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Sonja ZehetmayerCentre for Medical Statistics, Informatics and Intelligent Systems, Section for Medical Statistics, Medical University of Vienna, Vienna, Austria.
Balazs DömeComprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Britt-Madeleine ArnsLandesklinikum Thermenregion Hochegg, Grimmenstein, Austria.
Walter KlepetkoComprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria.
Christoph C ZielinskiDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Sabine Zöchbauer-MüllerDepartment of Medicine I, Clinical Division of Oncology, Medical University of Vienna, Vienna, Austria.
Comprehensive Cancer Center Vienna · ATMedical University of Vienna · ATStatistics Austria · ATOrszágos Korányi Tbc és Pulmonológiai Intézet · HUSalzburger Landeskliniken · AT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Deregulated DNA methylation leading to transcriptional inactivation of certain genes occurs frequently in non-small-cell lung cancers (NSCLCs). As well as protein-coding genes, microRNA (miRNA)-coding genes may be targets for methylation in NSCLCs; however, the number of known methylated miRNA genes is still small. Thus, we investigated methylation of miRNA genes in primary tumour (TU) samples and corresponding non-malignant lung tissue (NL) samples of 50 NSCLC patients by using methylated DNA immunoprecipitation followed by custom-designed tiling microarray analyses (MeDIP-chip), and 252 differentially methylated probes between TU samples and NL samples were identified. These probes were annotated, which resulted in the identification of 34 miRNA genes with increased methylation in TU samples. Some of these miRNA genes were already known to be methylated in NSCLCs (e.g. those encoding miR-9-3 and miR-124), but methylation of the vast majority of them was previously unknown. We selected six miRNA genes (those encoding miR-10b, miR-1179, miR-137, miR-572, miR-3150b, and miR-129-2) for gene-specific methylation analyses in TU samples and corresponding NL samples of 104 NSCLC patients, and observed a statistically significant increase in methylation of these genes in TU samples (p < 0.0001). In silico target prediction of the six miRNAs identified several oncogenic/cell proliferation-promoting factors (e.g. CCNE1 as an miR-1179 target). To investigate whether miR-1179 indeed targets CCNE1, we transfected miR-1179 gene mimics into CCNE1-expressing NSCLC cells, and observed downregulated CCNE1 mRNA expression in these cells as compared with control cells. Similar effects on cyclin E1 expression were seen in western blot analyses. In addition, we found a statistically significant reduction in the growth of NSCLC cells transfected with miR-1179 mimics as compared with control cells. In conclusion, we identified many methylated miRNA genes in NSCLC patients, and found that the miR-1179 gene is a potential tumour cell growth suppressor in NSCLCs. Overall, our findings emphasize the impact of miRNA gene methylation on the pathogenesis of NSCLCs. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.

Indexed as

DNA MethylationA549 CellsBiomarkers, TumorCarcinoma, Non-Small-Cell LungCell ProliferationChromatin ImmunoprecipitationCpG IslandsFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticGene Regulatory NetworksGenetic Predisposition to DiseaseHumansLung NeoplasmsMaleMicroRNAsBiomarkers, TumorMicroRNAsMIRN1179 microRNA, humanCpG island methylationMeDIP-chipmiRNAMS-HRM analysisnon-small-cell lung cancer

Identifiers

PMID29570800
PMCPMC6055722
OpenAlexW2791158854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.